BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...as Herceptin trastuzumab, Keytruda pembrolizumab or Rituxan rituximab.Gilead...
...escalation study combining lemzoparlimab with pembrolizumab or rituximab.Trillium...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...as Herceptin trastuzumab, Keytruda pembrolizumab or Rituxan rituximab.Gilead...
...escalation study combining lemzoparlimab with pembrolizumab or rituximab.Trillium...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...the shortfall. Sales of Avastin bevacizumab, Rituxan/MabThera rituximab...
BioCentury | Oct 9, 2020
Translation in Brief

Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine

...boosted numbers of tumor-infiltrating lymphocytes and raised levels of proinflammatory cytokines in the tumor microenvironment.Nordic radiotherapy reduces rituximab...
...use of betalutin (177Lu-satetraxetan-lilotomab) to reverse rituximab resistance in a xenograft mouse model of non-Hodgkin's lymphoma . The radioimmunotherapy plus rituximab...
BioCentury | Oct 6, 2020
Emerging Company Profile

Scribe: engineering CRISPR’s next generation

Scribe is carving out a new space in the gene editing landscape with a next-generation version of the technology from Jennifer Doudna’s lab that substitutes engineered CRISPR enzymes for their natural counterparts. Scribe Therapeutics Inc....
BioCentury | Sep 16, 2020
Product Development

Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline

...typically have poor outcomes, and while Rituxan rituximab...
...57% ORR, just 14% were complete responses. Rituxan...
...regimen. The current standard of care is Rituxan...
BioCentury | Jul 11, 2020
Translation in Brief

Peptide blocker of myeloid checkpoint; plus a magnet-based device to collect circulating tumor cells, severe vs. mild COVID-19 immune cell profiles and more

...melanoma enhanced an anti-TYRP1 antibody-mediated reduction in lung metastases. Combining the peptide with anti-CD20 mAb rituximab...
BioCentury | Jun 26, 2020
Emerging Company Profile

Artiva launches with $78M to develop Korean biotech’s NK cell programs outside Asia

...mAbs can affect health outcomes from the antibody treatments; the company will test AB-101 plus rituximab...
BioCentury | Jun 2, 2020
Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

...death 1 TNFα - tumor necrosis factor α Hongjiang Li, Staff Writer Biosimilar trastuzumab (GB221) Biosimilar infliximab (GB242) Biosimilar rituximab...
BioCentury | Apr 14, 2020
Deals

Expanded deal with Kyowa could give MEI cash through drug approval

...89% among 55 patients with follicular lymphoma. Some patients received ME-401 in combination with Rituxan rituximab...
...PI3Kγ. ME-401 is also in a Phase Ib trial as monotherapy and in combination with Rituxan...
Items per page:
1 - 10 of 4231